Aspire Biopharma (ASBP) Stock Price, News & Analysis

Company Overview

Aspire Biopharma Inc. is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis. In addition to epinephrine, Aspire has in-licensed a portfolio of novel PDE3/4 inhibitor compounds intended for maintenance therapy in chronic obstructive pulmonary disease (COPD) and severe asthma. Aspire’s development strategy emphasizes efficient clinical pathways and leveraging existing safety data to accelerate regulatory review.

Founded in 2007 and headquartered in Henderson, Nevada, Aspire Biopharma serves the U.S. market while exploring international licensing and distribution opportunities. The company maintains partnerships with contract development and manufacturing organizations (CDMOs) to support scalable production of its inhalation devices and formulations. Aspire’s leadership team combines expertise in pharmaceutical R&D, regulatory affairs, and pulmonary device engineering to drive its product pipeline toward late-stage clinical and market readiness.

Through strategic collaborations and targeted R&D investments, Aspire aims to address unmet medical needs in emergency medicine and chronic respiratory care. By focusing on inhaled delivery of both established and novel compounds, the company seeks to offer differentiated treatment options that improve patient outcomes and streamline acute care interventions.

Key Stats

• Today's Range: $4.82 to $6.00
• 50-Day Range: $0.19 to $39.60
• 52-Week Range: $3.31 to $1,050.36
• Volume: 199,273 shs
• Average Volume: 1.36 million shs
• Market Capitalization: $997.90 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Aspire Biopharma Stock Analysis - MarketRank™

Aspire Biopharma scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Aspire Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Aspire Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aspire Biopharma is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aspire Biopharma is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.36% of the float of Aspire Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Aspire Biopharma has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aspire Biopharma has recently increased by 120.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aspire Biopharma does not currently pay a dividend.

Dividend Growth

Aspire Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: -0.26

News Sentiment

Aspire Biopharma has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Aspire Biopharma this week, compared to 2 articles on an average week.

Search Interest

18 people have searched for ASBP on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.

MarketBeat Follows

3 people have added Aspire Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aspire Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.80% of the stock of Aspire Biopharma is held by insiders.

Percentage Held by Institutions

19.17% of the stock of Aspire Biopharma is held by institutions.

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASBP
• Previous Symbol: NASDAQ:PWUP
• CIK: 1847345
• Web: N/A
• Phone: (561) 704-8527
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($20.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.48 million
• Net Margins: N/A
• Pretax Margin: -394,727.50%
• Return on Equity: N/A
• Return on Assets: -1,468.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 99.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($54.19) per share
• Price / Book: -0.11

Miscellaneous

• Outstanding Shares: 170,000
• Free Float: 157,000
• Market Cap: $997.90 thousand
• Optionable: N/A
• Beta: 0.21